Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of resiquimod gel in actinic keratosis
2012-003589-42Phase 2Terminated
- Sponsor
- Galderma
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of resiquimod in actinic keratosis (AK), sponsored by Galderma. Primary endpoints: Recurrence rate of AK lesions at 6 months and Recurrence rate of AK lesions at 12 months. Started Dec 2012; status: terminated.
02
Drugs
resiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2012-003589-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003589-42.